Handling Non-Standard Data: Devices, Digital Biomarkers and RWD

Published on 17/11/2025

Handling Non-Standard Data: Devices, Digital Biomarkers and RWD

Clinical trials play a vital role in advancing medical knowledge and improving patient outcomes. However, the landscape of data management is continuously evolving, particularly with the integration of non-standard data sources such as devices, digital biomarkers, and real-world data (RWD). This comprehensive tutorial outlines the best practices for handling non-standard data in clinical trials, focusing on regulatory compliance and data standards, especially within the context of ICH-GCP, FDA, EMA, and MHRA guidelines.

Understanding Non-Standard Data in Clinical Trials

The term “non-standard data” encompasses a variety of data types that may not fit into traditional clinical trial data collection frameworks. These include:

Device-generated data: Information collected from medical devices, including wearables and remote monitoring systems.
Digital biomarkers: Data derived from digital assessments that can provide insights into health and disease states.
Real-world data (RWD): Data collected outside of conventional clinical trials, including electronic health records, claims data, and patient registries.

Understanding these components is crucial for clinical operations, regulatory affairs, and medical affairs professionals who manage clinical trials for dental implants and other medical interventions. Effective integration of this data can enhance the robustness of study findings and support regulatory submissions.

Regulatory Framework for Non-Standard Data

In the US, UK, and EU, regulatory bodies have established guidelines to ensure that clinical trial data — including non-standard data — are collected and analyzed with integrity. Familiarity with these guidelines is essential for compliance and successful trial execution.

The FDA acknowledges the potential value of RWD and has issued guidelines to streamline its use in regulatory decision-making, particularly in studies concerning conditions like ankylosing spondylitis clinical trials. The EMA has followed suit, encouraging the integration of relevant RWD in their methodological frameworks.

Moreover, the MHRA‘s guidance on clinical trials emphasizes the need for data quality and reusability, paving the way for data from devices and digital sources to be considered trustworthy in the regulatory assessment process. Understanding the nuances of these guidelines allows professionals to navigate the complexities involved in collecting and analyzing non-standard data.

Best Practices for Managing Non-Standard Data in Clinical Trials

To effectively manage non-standard data in clinical trials, a systematic approach is essential. Here are the key steps:

1. Define Objectives and Data Sources

Start by clearly defining the objectives of the clinical trial and identifying the types of non-standard data that will be relevant. This may include:

Data from wearable devices that track biometrics.
Surveys and patient-reported outcomes (PROs) collected via applications.
Data extracted from electronic health records (EHR) relating to previous treatment efficacy.

In the context of sma clinical trials, for instance, determining how real-time data can be utilized to assess treatment outcomes statistically can provide significant insights.

2. Establish Data Standards

Next, establish robust data standards following the principles set forth by the Clinical Data Interchange Standards Consortium (CDISC). The CDISC SDTM (Study Data Tabulation Model) and ADaM (Analysis Data Model) are essential frameworks for structuring clinical trial data consistently.

Implementing these standards enables the integration of non-standard data more efficiently, improving the comparability of results across clinical trials. For device-generated data, develop a strategy to ensure that data can be standardized to fit within these models.

3. Ensure Data Integrity

A crucial component of managing non-standard data is ensuring data integrity. This involves implementing rigorous quality controls at multiple stages, including:

Data Collection: Utilize validated tools for data collection to minimize errors.
Data Storage: Employ secure, compliant data storage solutions that protect patient privacy and data security.
Data Analysis: Conduct thorough data review and validation before analysis to identify discrepancies.

For clinical trials involving lecanemab, oversight in data integrity becomes even more critical, as the findings will be closely scrutinized in the regulatory submission process.

4. Engage Stakeholders

Throughout the trial, maintaining open communication with stakeholders, including regulatory bodies, sponsors, and patient advocacy groups, is essential. Engage them early in the planning process to align on expectations and incorporate feedback into your data collection strategies. This collaboration can assist in refining the methodologies leveraged during the trial.

5. Train Personnel

Ensure that all personnel involved in data collection and management are adequately trained in handling non-standard data. Training programs should cover:

Data collection tools and technologies.
CDISC standards and regulatory requirements.
Best practices for data integrity and quality controls.

A well-trained team is vital for consistent, accurate data management, reducing the likelihood of compliance issues during audits.

Challenges in Handling Non-Standard Data

Managing non-standard data involves several challenges that clinical operations, regulatory affairs, and medical affairs professionals must address:

1. Data Integration

Integrating data from diverse sources can be a significant hurdle. It requires consistent methodologies to convert different data types into formats that comply with regulatory standards. For example, combining EHR data with data from wearables may necessitate substantial data harmonization efforts to use them effectively in statistical analyses.

2. Data Privacy and Security

Ensuring patient privacy and the security of sensitive health information is paramount. Clinical trials that collect non-standard data must comply with regulations such as HIPAA in the US and GDPR in the EU. Developing a robust data governance strategy can help mitigate these risks.

3. Time and Resource Intensive

The process of establishing protocols for non-standard data management can be time-consuming and resource-intensive. Proper planning and allocation of resources are crucial to ensuring that the clinical trial remains on schedule while adhering to regulatory standards.

Future Trends in Non-Standard Data Management

The use of non-standard data in clinical trials is expected to continue growing. Key trends include:

1. Increased Use of AI and Machine Learning

Artificial Intelligence (AI) and machine learning technologies are gaining traction in analyzing non-standard data. These tools can automate data processing, enhance predictive analytics, and improve trial design by providing insights powered by real-world evidence.

2. Greater Patient Engagement

With the rise of patient-centric trial designs, digital tools that facilitate real-time feedback from participants are becoming crucial. These tools can enhance data quality by allowing patients to report outcomes more conveniently.

3. Advancements in Regulatory Guidelines

Regulatory bodies are continually updating their guidelines to accommodate innovations in data use. Understanding these changes will be critical for clinical operations professionals to maintain compliance and leverage new opportunities for data integration. For more information, resources such as FDA can provide comprehensive insights into evolving regulatory paradigms.

Conclusion

In summary, handling non-standard data in clinical trials requires a thoughtful, structured approach that prioritizes regulatory compliance, data integrity, and stakeholder engagement. By adhering to established data standards and best practices outlined in this guide, clinical operations, regulatory affairs, and medical affairs professionals can effectively manage non-standard data to improve trial outcomes and ensure regulatory success.

As the landscape of clinical trials continues to evolve, embracing the integration of non-standard data will not only enhance the quality of research but also contribute to more personalized and effective healthcare solutions.